Leung MW, Bazelier MT, Souverein PC, Uitdehaag BM, Klungel OH, Leufkens HG, Pajouheshnia R. Mapping the risk of infections in patients with multiple sclerosis: a multi-database study in the United Kingdom clinical practice research datalink GOLD and aurum. Mult Scler. 2022 Oct;28(11):1808-18. doi: 10.1177/13524585221094218.
Mauskopf J, Chirila C, Birt J, Boye KS, Bowman L. Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: have they impacted the National Health Service budget? Health Policy (New York). 2013 Apr 1;110(1):49-59.
Meads DM, Doward LC, McKenna SP, Fisk J, Twiss J, Eckert B. The development and validation of the Unidimensional Fatigue Impact Scale (U-FIS). Mult Scler. 2009 Oct 1;15(10):1228-38. doi: 10.1177/1352458509106714
Miret M, Perez-Gutthann S, Gutierrez LP, Viglietta V, Musch B, Greenberg S. Evaluation of the long-term safety of Cladribine tablets: design of a prospective 8-year safety registry. Poster presented at the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS); 2009. Dusseldorf, Germany. [abstract] Mult Scler. 2009 Sep 8; 15(Issue Suppl_9):S239. doi: 10.1177/1352458509106963
Doward LC, McKenna SP, Meads DM, Twiss J, Eckert BJ. The development of Patient Reported Outcome Indices for Multiple Sclerosis (PRIMUS). Mult Scler. 2009 Sep 1;15(9):1092-102.
Richter A, Hicks KA, Earnshaw SR, Honeycutt AA. Allocating HIV prevention resources: a tool for state and local decision making. Health Policy (New York). 2008 Sep 1;87(3):342-9.
Doward LC, McKenna SP, Meads DM, Twiss J, Hagell P, Oprandi N. Psychometric and scaling properties of the patient reported outcome indices for multiple sclerosis (PRIMUS). Mult Scler. 2007 Jun;13(Suppl 2):S219.
Doward LC, Meads DM, Fisk JD, McKenna SP, Eckert BJ. Derivation of a unidimensional scale from the fatigue impact scale. Mult Scler. 2006 Sep;12(Suppl 1):S1-S228.
Tsianos G, Eleftheriou KI, Hawe E, Woolrich L, Watt M, Watt I, Peacock A, Montgomery H, Grant S. Performance at altitude and angiotensin I-converting enzyme genotype. Eur J Appl Physiol. 2005;93(5-6):630-3.
James L, Onambele G, Woledge R, Skelton D, Woods D, Eleftheriou K, Hawe E, Humphries SE, Haddad F, Montgomery H. IL-6-174G/C genotype is associated with the bone mineral density response to oestrogen replacement therapy in post-menopausal women. Eur J Appl Physiol. 2004;92(1-2):227-30.
Woods D, Sanders J, Jones A, Hawe E, Gohlke P, Humphries SE, Payne J, Montgomery H. The serum angiotensin-converting enzyme and angiotensin II response to altered posture and acute exercise, and the influence of ACE genotype. Eur J Appl Physiol. 2004;91(2-3):342-8.
Dhamrait SS, James L, Brull DJ, Myerson S, Hawe E, Pennell DJ, World M, Humphries SE, Haddad F, Montgomery HE. Cortical bone resorption during exercise is interleukin-6 genotype-dependent. Eur J Appl Physiol. 2003 Mar;89(1):21-5.
Lovas K, Kalo Z, McKenna SP, Whalley D, Pentek M, Genti G. Establishing a standard for patient-completed instrument adaptations in Eastern Europe: experience with the Nottingham Health Profile in Hungary. Health Policy (New York). 2003 Jan 1;63(1):20.
McKenna SP, Whalley D. Assessment of biotechnology drugs: what are the issues? Letter to the editor. Health Policy (New York). 1999 Nov;49(3):195-7. doi: 10.1016/S0168-8510(99)00055-X